Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy

被引:26
|
作者
Fang, Likui [1 ]
Wang, Luming [1 ]
Wang, Yiqing [1 ]
Lv, Wang [1 ]
Hu, Jian [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Thorac Surg, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
基金
国家重点研发计划;
关键词
Locally advanced lung squamous cell carcinoma; Neoadjuvant chemotherapy; Video assisted thoracic surgery; Thoracotomy; INDUCTION CHEMORADIOTHERAPY; THORACOSCOPIC LOBECTOMY; CANCER; THERAPY; N0; CHEMORADIATION; COMPLICATIONS; RADIOTHERAPY; METAANALYSIS; RESECTION;
D O I
10.1186/s13019-018-0813-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundSurgery is an important part of multidisciplinary treatment strategy for locally advanced lung squamous cell carcinoma (LSCC), but insufficient evidence supports the feasibility and safety of video assisted thoracic surgery (VATS) following neoadjuvant chemotherapy for locally advanced LSCC. This study aims to compare perioperative data and long-term survival of locally advanced LSCC patients between VATS and thoracotomy after neoadjuvant chemotherapy.MethodsWe retrospectively collected the clinical and pathological information of patients with locally advanced LSCC who underwent surgical resection after neoadjuvant chemotherapy from October 2013 to October 2017. All patients were divided into two groups (thoracotomy and VATS) and were compared the differences in perioperative, oncological and survival outcomes.ResultsA total of 81 patients were analyzed in this study (67 thoracotomy and 14 VATS). VATS provided less postoperative pain (P=0.005) and produced less volume of chest drainage (P=0.019) than thoracotomy, but the number of resected lymph nodes was less in VATS group (P=0.011). However, there was no significant difference in the number of resected lymph node stations and the rate of nodal upstaging between two groups. The mean disease free survival (DFS) was 32.72.7months for the thoracotomy group and 31.8 +/- 3.0months for the VATS group (P=0.335); the corresponding overall survival (OS) was 41.7 +/- 2.2months and 36.4 +/- 4.1months (P=0.925).Conclusion In selected patients with locally advanced LSCC, VATS played a positive role in postoperative recovery and associated similar survival outcome compared with thoracotomy after neoadjuvant chemotherapy.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma
    Yang, Xinyu
    Yin, Hao
    Zhang, Shaoyuan
    Jiang, Tian
    Gu, Jianmin
    Jiao, Heng
    Wang, Hao
    Liang, Fei
    Xu, Songtao
    Fan, Hong
    Ding, Jianyong
    Ge, Di
    Wang, Qun
    Yin, Jun
    Tan, Lijie
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2025, 169 (01)
  • [42] Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma
    Wang, Zhen
    Chen, Xiankai
    Li, Yong
    Qin, Jianjun
    Fang, Yuan
    Yang, Zhaoyang
    Fang, Yan
    Qu, Dong
    Zhang, Ruixiang
    Zheng, Qingfeng
    Kang, Xiaozheng
    Xue, Liyan
    Huang, Jing
    Li, Yin
    He, Jie
    JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (02): : 98 - 105
  • [43] Patterns and Influence of Lymph Nodal Metastases After Neoadjuvant Chemotherapy and Surgery for Thoracic Esophageal Squamous Cell Carcinoma
    Sun, Hai-Bo
    Jiang, Duo
    Liu, Xian-Ben
    Xing, Wen-Qun
    Chen, Pei-Nan
    Feng, Shao-Kang
    Yan, Sen
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (08) : 5205 - 5212
  • [44] Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
    Liu, Jiacong
    Zhu, Linhai
    Huang, Xuhua
    Lu, Zhongjie
    Wang, Yanye
    Yang, Yuhong
    Ye, Jiayue
    Gu, Chen
    Lv, Wang
    Zhang, Chong
    Hu, Jian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (03)
  • [45] Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma
    Lee, Yoo Na
    Sung, Min Kyu
    Hwang, Dae Wook
    Park, Yejong
    Kwak, Bong Jun
    Lee, Woohyung
    Song, Ki Byung
    Lee, Jae Hoon
    Yoo, Changhoon
    Kim, Kyu-Pyo
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    Kim, Song Cheol
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1240 - 1251
  • [46] Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery
    Junya Oguma
    Koshiro Ishiyama
    Daisuke Kurita
    Kyohei Kanematsu
    Yusuke Fujii
    Kentaro Kubo
    Shun Yamamoto
    Yoshitaka Honma
    Ken Kato
    Hiroyuki Daiko
    Esophagus, 2022, 19 : 214 - 223
  • [47] Patterns of Regional Lymph Node Recurrence After Radical Surgery for Thoracic Esophageal Squamous Cell Carcinoma
    Wu, San-Gang
    Dai, Ming-Ming
    He, Zhen-Yu
    Sun, Jia-Yuan
    Lin, Huan-Xin
    Lin, Hui
    Li, Qun
    ANNALS OF THORACIC SURGERY, 2016, 101 (02) : 551 - 557
  • [48] Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
    Yu, Yong-kui
    Meng, Fan-Yu
    Wei, Xiu-feng
    Chen, Xian-kai
    Li, Hao-miao
    Liu, Qi
    Li, Can-jun
    Xie, Hou-nai
    Xu, Lei
    Zhang, Rui-xiang
    Xing, Wenqun
    Li, Yin
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 168 (02)
  • [49] Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Qian, Ting
    Liu, Delin
    Cao, Guochun
    Chen, Zhipeng
    Zhang, Qin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [50] Neoadjuvant chemotherapy to radiation and concurrent chemoradiation for locally advanced squamous cell carcinoma of the cervix: A review of the recent literature
    Colombo, A
    Landoni, F
    Maneo, A
    Zanetta, G
    Nava, S
    Tancini, G
    TUMORI JOURNAL, 1998, 84 (02): : 229 - 237